Report cards › Food › King's Hawaiian Bakery West

KING'S HAWAIIAN

Owned by King's Hawaiian Bakery West · 38 products in USDA FoodData Central · as of Oct 29, 2026 · Report an error · Change log

CSWH grade B (77)

Method v1.0 (how we grade), based on the records below; exact score 77.

Grade by indicator
IndicatorGradeWhat we found
Recalls (40%)B (80)1 Class II (4 points) · 1 event For current recalls see FDA and USDA.
Ingredients (40%)C (63)Tier A: 0 of 38 products · A (100) (25%)
Tier B: 30 of 38 products (DATEM) · F (0) (15%) · products
FDA warning letters (20%)A (100)None found to the owner Oct 29, 2021 to Oct 29, 2026.

Shown, not graded: recall reasons (1 foreign material) · IARC notes (1 product) · FDA dye pledge: none on FDA's tracker.

Recalls, Oct 29, 2021 to Oct 29, 2026

  1. Class II, Nov 15, 2021 · Foreign material · FDA event 89061

    • Kings Hawaiian Hawaiian Sweet Hamburger Buns8 buns NET WT 12.8 oz. (362.9 g) UPC 0 73435-06050 Product Number 800020

      Reason (FDA's words)
      Products that were on HOLD for potential foreign materials was accidently released into commerce. The products released may be contaminated with small plastic foreign material.
      Code information
      Lot Code 081122; Time Stamp HH:MM 12:40 14:05- Frozen Best By Date 03/22/2022
      Recalling firm
      King's Hawaiian Bakery
      Dates
      Recall started Nov 15, 2021; classified Nov 24, 2021
      Status
      Terminated (status reported by FDA at classification)
      How we matched it
      matched by UPC 73435060505 (upc)

      FDA record F-0215-2022: openFDA · Report an error

Store-brand and co-packer recalls count on a brand only when a UPC in the recall matches one of its products.

Ingredients on our watch list

Products (31)

Show all 31 products

Labels change: each row shows the date of its FoodData Central record. A brand that has changed a recipe can report it with "Report an error".

FDA warning letters to King's Hawaiian Bakery West, Oct 29, 2021 to Oct 29, 2026

None found from FDA food offices.

FDA notes that later events may have changed the regulatory status of what a letter discusses.